Ruxolitinib Switch-Maintenance Prophylaxis of GVHD
Randomized Pilot Study of Ruxolitinib for Switch-Maintenance Prophylaxis of Graft-versus-Host Disease in Allogeneic Hematopoietic Cell Transplantation After Intermediate-Dose Post-Transplant Cyclophosphamide (Rux Switch-Maintenance in Intermediate PTCY: RuSMa-PTCY) in Comparison to Full-Dose PTCY
Arms / Cohorts
Experimental:An intermediate dose (medium dose) of PTCY, tacrolimus, MMF, and the drug ruxolitinib
Accepting patients
Active Comparator:A full dose of PTCY, tacrolimus, and MMF (the standard GVHD prevention approach)
Accepting patients
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.